Kalaris CMO granted 135,000 stock options

Kalaris Therapeutics, Inc. reported that Chief Medical Officer Matthew Feinsod received a grant of stock options covering 135,000 shares of common stock.

Accepted by SEC EDGAR 03/20/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kalaris Therapeutics, Inc. reported that Chief Medical Officer Matthew Feinsod received a grant of stock options covering 135,000 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 18, 2036.

According to the vesting terms, 25% of the underlying shares are scheduled to vest on March 19, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service. After this grant, Feinsod holds options for 135,000 shares directly.

Insider Trade Summary

Grant/Award: 135,000 shares

Grant/Award 1 txn

Insider Feinsod Matthew

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	135,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 135,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kalaris Therapeutics (KLRS) disclose for Matthew Feinsod?

Kalaris Therapeutics disclosed that Chief Medical Officer Matthew Feinsod received a grant of stock options for 135,000 shares of common stock. The grant is compensation-related, not an open-market trade, and is reported as an acquisition under Form 4 with code A.

How many Kalaris Therapeutics (KLRS) shares are covered by the new stock options?

The reported stock option grant covers 135,000 shares of Kalaris Therapeutics common stock. These options give the right to buy shares at a fixed exercise price, subject to the vesting schedule and expiration terms disclosed in the Form 4 filing.

What is the exercise price and expiration date of the KLRS options granted to the CMO?

The options granted to the Chief Medical Officer have an exercise price of $6.81 per share and expire on March 18, 2036. This means they can be exercised at $6.81 any time after vesting and before the stated expiration date, assuming continued service conditions are satisfied.

How do the Kalaris Therapeutics (KLRS) options granted to Matthew Feinsod vest over time?

The shares underlying the option vest over four years. Twenty-five percent of the option shares vest on March 19, 2027, and the remaining 75% vest in equal monthly installments thereafter, as long as Matthew Feinsod maintains continuous service with Kalaris Therapeutics during the vesting period.

Did the KLRS Form 4 show any open-market buying or selling of common stock?

No, the Form 4 shows a grant of a stock option, not open-market buying or selling. The transaction is coded A, indicating a grant or award acquisition of derivative securities, with no reported purchase or sale of common shares in the market.

What are Matthew Feinsod’s reported holdings after the Kalaris Therapeutics option grant?

After the grant, the filing reports that Matthew Feinsod directly holds stock options covering 135,000 shares of Kalaris Therapeutics common stock. This total reflects the newly awarded derivative position as disclosed in the Form 4 transaction details and holding summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feinsod Matthew

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE, SUITE 5500

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.81	03/19/2026		A		135,000		(1)	03/18/2036	Common Stock	135,000	$0	135,000	D

Explanation of Responses:

1. The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

	/s/ Brett Hagen, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)